Hospital Pharmacy Europe

APRIL 12, 2023

Hear the latest developments and innovations in cardiovascular care at a new free event being held in May 2023 In support of our mission to provide high-quality clinical education, Hospital Healthcare Europe , together with Hospital Pharmacy Europe, is proud to announce a new series of events in 2023: the HHE Clinical Excellence programme.

Hospitals 95

Hospitals 95

Hospital Pharmacy Europe

FEBRUARY 1, 2024

Kicking off on 19 March 2024, Clinical Excellence in Cardiovascular Care is a one-day cardiology event for the multidisciplinary team exploring the latest advances in cardiology – and registration is now open. The post Clinical Excellence in Cardiovascular Care returns with new event for the MDT appeared first on Hospital Pharmacy Europe.

Hospitals 52

Hospitals Patient Care 52

STAT

DECEMBER 7, 2022

“I think we need to actually start policing ourselves better,” Brawley, a professor of oncology and epidemiology at John Hopkins University and former chief medical officer and executive vice president at the American Cancer Society, said at a STAT virtual event on Tuesday. Read the rest…

97

97

STAT

JUNE 5, 2023

On Sunday, Richard Pazdur, director of the FDA’s Oncology Center of Excellence, took issue with his boss. It’s true that the FDA has no obligation to follow what the advisory committee recommends, but the votes help, Pazdur said at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

FDA 94

FDA 94

pharmaphorum

AUGUST 24, 2020

Could collecting, understanding, and disseminating patient-reported outcomes during trials be the key to advancing oncology treatments and improving cancer outcomes? . Project Patient Voice is a dedicated online platform that makes patient-reported symptoms and adverse events (AEs) from the trial data of marketed drugs publicly available.

Labelling 128

Labelling Communication FDA 128

pharmaphorum

SEPTEMBER 30, 2022

Genetic testing has become vastly more accessible in the last 20 years and has opened all kinds of doors in medicine, from pharmacogenetics and better understanding drug interactions and adverse events to tremendous advances in oncology: understanding the underlying genetics of cancer cells has allowed delivery of affective, targeted treatments.

98

98

Hospital Pharmacy Europe

DECEMBER 18, 2023

To this end, the Society of Geriatric Oncology and the French Society of Oncology Pharmacists have published a position paper to support this collaboration. Here, Chloé Herledan PharmD PhD, pharmacist, Clinical Oncology Pharmacy Unit, Hospices Civils de Lyon and Université Claude Bernard Lyon 1, Lyon, France, shares an overview.

Chemotherapy 96

Chemotherapy Hospitals Labelling Communication 96

European Pharmaceutical Review

OCTOBER 18, 2022

The ZUMA-7 study demonstrated that treated patients had a four-fold greater improvement in the primary endpoint of event-free survival over the current SOC (8.3 3 cytokine release syndrome (CRS) and neurologic events were observed in 6 percent and 21 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred.

Chemotherapy 105

Chemotherapy 105

European Pharmaceutical Review

JANUARY 10, 2024

“It is early, but we saw some promising results that this vaccine may help many of these patients avoid relapse, which could increase survival,” principal investigator Dr Shubham Pant, Associate Professor of Gastrointestinal Medical Oncology, explained. “It It also showed a favourable safety profile, which is exciting.”

Vaccines 91

Vaccines Chemotherapy 91

Pharmaceutical Technology

AUGUST 8, 2022

Time to progression in pain, castration-resistant prostate cancer, first symptomatic skeletal event, the commencement of successive anticancer treatment, all analysed at 12?week week intervals, as well as adverse events (AEs) as a measure of safety and tolerability were the trial’s secondary endpoints.

FDA 98

FDA Chemotherapy 98

European Pharmaceutical Review

JUNE 6, 2023

These results were presented in an abstract at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Adverse events at Grade 3 or higher from all causes occurred in 23 percent of patients in the TAGRISSO arm versus 14 percent in the placebo arm.

95

95

pharmaphorum

NOVEMBER 15, 2021

Arriving at a critical point for TIGIT development, the 2nd Annual TIGIT Therapies Summit is the definitive industry-led event focused on propelling this next-generation inhibitor to clinical use. Plus 2 add on workshops: • Elucidating the anti-tumor immunity of other immune checkpoint inhibitors in oncology.

Medical Schools 52

Medical Schools Immunization Hospitals 52

European Pharmaceutical Review

FEBRUARY 15, 2023

The results suggest “that neoadjuvant nivolumab was safe in long-term follow-up,” commented Patrick Forde, MBBCh, an Associate Professor of oncology and Director of the Thoracic Oncology Clinical Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Neoadjuvant nivolumab did not lead to surgical delays.

Chemotherapy 92

Chemotherapy Immunization FDA 92

pharmaphorum

APRIL 6, 2021

With high stakes to satisfy unmet patient needs, cell therapy is a promising but challenging field of oncology. Taking place as a fully interactive digital event, this is y our chance to hear the latest advances and innovations in the preclinical cell therapy space. There is a crucial need to progress candidates from bench to bedside.

Medical Schools 52

Medical Schools 52

STAT

JUNE 7, 2023

What did we learn from this year’s annual meeting of the American Society of Clinical Oncology? Earlier this year, one of the first children cured with this tech, Emily Whitehead, spoke at a STAT event. Now she’s 18. Continue to STAT+ to read the full story…

Patient Care 89

Patient Care 89

Viseven

OCTOBER 5, 2023

Digital Pharma East is a captivating event for professionals who want to improve their expertise in advertising, sales, brand marketing, customer experience, digital marketing, PR, product marketing, social media, and strategic operations. For Viseven, it was a big honor to attend the event as one of the bronze partners.

52

52

pharmaphorum

NOVEMBER 17, 2020

Are you interested in finding the next breakthrough in immuno-oncology preclinical or clinical development? Recent scientific, clinical breakthroughs and high-profile industry deals have reignited the race to find the next blockbuster TGF-ß inhibitor for immuno-oncology applications. Take a look at the full program here.

52

52

Hospital Pharmacy Europe

AUGUST 7, 2023

The approval in both markets is based on the findings of the phase 3 SUNLIGHT trial , conducted by Servier and Taiho Oncology, and published in the New England Journal of Medicine in May 2023. In addition, the median progression free survival 5.6 months in the trifluridine/tipiracil with bevacizumab group compared to 2.4

FDA 98

FDA Chemotherapy Hospitals 98

Hospital Pharmacy Europe

OCTOBER 31, 2022

Prophylactic irradiation of patients with asymptomatic bone metastases reduces skeletal-related events, hospitalisation and improves survival. The team therefore wondered if prophylactic irradiation of asymptomatic bone metastases might prevent future skeletal-related events. Prophylactic irradiation and skeletal-related events.

Hospitals 52

Hospitals 52

pharmaphorum

DECEMBER 8, 2022

See the complete 2023 event guide here. Our line-up of 20+ industry leading expert speakers includes: Vicky Appleman , STING Discovery Lead (Principal Scientist), Takeda Oncology. James Palacino , Vice President, Head of Biology, Orum Therapeutics. Oxana Beskrovnaya , Chief Scientific Officer, Dyne Therapeutics.

52

52

pharmaphorum

APRIL 19, 2022

With Keynote sessions from Ikena Oncology, Spring Works Therapeutics, Cedilla and Vivace Therapeutics, this is a unique opportunity to hear first-hand the development of novel YAP/TAZ-TEAD antagonists, from discovery to the clinic. Download the full event guide here.

52

52

Pharmaceutical Technology

SEPTEMBER 5, 2022

Soriot said AstraZeneca is particularly interested in oncology, cardiovascular disease, and rare diseases, and taking part in more ‘small to mid-size’ bolt-on acquisitions in the upcoming years. “We In this period, AstraZeneca has also taken part in five oncology and respiratory disease deals, respectively. billion in development.

FDA 114

FDA Vaccines 114

pharmaphorum

APRIL 20, 2021

View the event guide now for the full agenda details and expert speaker faculty. Dive into the exciting advancements in the NSCLC rare mutations space, with the novel therapies in targeting BRAF, NGR1 fusions and HER2 with Kinnate Biopharmaceuticals, Elevation Oncology and Boeringer Ingelheim.

Medical Schools 52

Medical Schools Immunization 52

PQA

JANUARY 26, 2023

PQA meetings and convening events are just one example of how members can engage with the wide array of health care stakeholders from across our membership. This year will feature a few familiar PQA events, each with its own focus and objectives, as well as some topic-based events focused on key areas that impact medication use.

Patient Care 40

Patient Care 40

PQA

DECEMBER 27, 2023

Building Consensus on Priorities for Improving Oncology Quality Measurement (August 29) PQA released an important report that we believe is a key step towards improving the quality of care for individuals using oral anticancer medications (OAM). As we close out 2023, here’s a look back at the top five blogs of the year.

52

52

pharmaphorum

MAY 27, 2022

With this, there has never been a hotter time to double down and deliver the holy grail of precision oncology as the true power of bispecifics is recognized. Download the Full Event Guide here for speakers, presentations, pricing and more. The post 13th World Multispecifics Summit appeared first on.

Immunization 52

Immunization 52

pharmaphorum

NOVEMBER 11, 2022

Download the full event guide here for the official agenda. Marc Pelletier , Senior Principal Scientist – Translational Immune Oncology, Novartis. Download your event guide to see what these experts will be discussing. Alan Watt , Chief Scientific Officer, NodThera.

Medical Schools 52

Medical Schools Immunization Hospitals 52

PQA

SEPTEMBER 8, 2023

Building Consensus to Improve Oncology Quality Measurement Recommendations to Improve the Quality of Oral Anticancer Medication Use is a new report that shares the consensus-based recommendations of 23 national experts and patients, who were convened by PQA, to prioritize opportunities for improving the quality of OAM use.

Community Pharmacies 52

Community Pharmacies 52

European Pharmaceutical Review

NOVEMBER 7, 2022

“The FDA’s Breakthrough Designation recognises the potential of elranatamab as an innovative medicine for multiple myeloma (MM) which has relapsed or is refractory to existing treatments,” shared Dr Chris Boshoff, Chief Development Officer for Oncology and Rare Disease at Pfizer Global Product Development. Elranatamab clinical trial data.

FDA 99

FDA 99

pharmaphorum

OCTOBER 13, 2021

The Gastrointestinal Cancer Drug Development Summit is the only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies, ADCs, and precision oncology to address the large unmet clinical need in GI cancers. Explore the full event guide here: [link]. **A

Immunization 52

Immunization 52

pharmaphorum

MARCH 22, 2021

Focus on Cell Characterization & Beyond Oncology – join a dedicated post-event day to explore preclinical characterization to CMC gold standards and debate the best indications for CAR-TCR technologies with the pioneers pushing the bounds of therapeutic application.

FDA 52

FDA 52

European Pharmaceutical Review

DECEMBER 14, 2022

Adverse events observed with mRNA-4157/V940 in KEYNOTE-942 were consistent with those previously reported in a Phase I clinical trial. Serious treatment-related adverse events (SAEs) occurred in 14.4 Safety data from the Phase IIb trial assessing an mRNA cancer vaccine plus KEYTRUDA ®.

Vaccines 111

Vaccines Immunization 111

European Pharmaceutical Review

AUGUST 17, 2022

The incidence of adverse events, including those of grade 3 or higher, during treatment was higher in the lutetium ( 177 Lu) vipivotide tetraxetan plus SOC group than in the SOC only group11. The most common treatment-emergent adverse events in those receiving lutetium ( 177 Lu) vipivotide tetraxetan plus SOC (all grades) were fatigue (43.1

Chemotherapy 117

Chemotherapy Compounding Labelling 117

Pharmaceutical Technology

JUNE 4, 2023

At the ongoing American Society of Clinical Oncology (ASCO) Annual Meeting, being held 2–6 June, new data was presented from the randomized, controlled Phase III KEYNOTE-671 study of MSD’s Keytruda (pembrolizumab) (abstract LBA100). months, the two-year event-free survival (EFS) was 62.4% At a median duration of follow-up of 25.2

Chemotherapy 75

Chemotherapy Hospitals FDA 75

pharmaphorum

DECEMBER 22, 2022

The results were published in the New England Journal of Medicine Evidence , as well as presented at the European Society for Medical Oncology Congress 2022. The updated results showed that the Imfinzi combination reduced risk of death by 24% compared to chemotherapy alone after an additional 6.5

Chemotherapy 63

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies 63

pharmaphorum

FEBRUARY 17, 2021

Roche and PatchAi have been working together on the Smart Health Companion (SHC), which was launched to oncology and haematology patients in July 2020, and will now step up their collaboration to offer it more widely.

Communication 105

Communication Patient Care 105

pharmaphorum

NOVEMBER 22, 2021

Celebrating 20 years of FDA approval and high efficacy profiles, kinase inhibitors have changed the face of oncology treatment. View the Full Event Guide here for the full speaker line-up and agenda details. However, increasing resistance and safety issues limit the success of existing kinase inhibitor classes.

Medical Schools 52

Medical Schools FDA 52